Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor
The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of: a) a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein R 1 —R 4 , p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.
1 . A method of treating breast cancer in a patient comprising administering to the patient therapeutically effective amounts of:
a) a compound of the Formula I:
or a pharmaceutically acceptable salt thereof and an erbB-2 inhibitor.
2 . The method of claim 1 wherein a tumor cell from said breast cancer expresses cMET.
3 . The method of claim 1 , wherein a tumor cell from said breast cancer overexpresses erbB-2.
4 . The method of claim 1 , wherein said erbB-2 inhibitor comprises a compound of Formula II
or a pharmaceutically acceptable salt thereof.
5 . The method of claim 1 , wherein said erbB-2 inhibitor comprises trastuzumab.
6 . The method of claim 1 , wherein said breast cancer is resistant to lapatinib or a pharmaceutically acceptable salt thereof or trastuzumab.
7 . The method of claim 1 , wherein said compound of Formula I and said erbB-2 inhibitor have a synergistic effect in inhibiting cell growth said breast cancer.
8 . The method of claim 1 wherein a tumor cell from said breast cancer expresses AXL.
9 . The method of claim 8 , wherein the tumor cell overexpresses AXL.
10 . A method of treating cancer in a patient in need thereof, comprising identifying if a tumor cell from said cancer expresses or overexpresses AXL and if said tumor cell expresses or overexpresses AXL administering a composition comprising Formula I and an erbB-2 inhibitor to said patient.
11 . The method of claim 10 wherein said cancer is resistant to lapatinib or a pharmaceutically acceptable salt thereof.
12 . The method of claim 10 wherein said cancer is resistant to trastuzumab.
13 . The method of claim 10 wherein said erbB-2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
14 . The method of claim 10 wherein said erbB-2 inhibitor is trastuzumab.
15 . The method of claim 10 wherein said cancer is breast cancer.